Taysha Gene Therapies, Inc. TSHA Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Taysha Gene Therapies, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s cash ratio?
- Taysha Gene Therapies, Inc. (TSHA) reported cash ratio of 13.8× in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s cash ratio changed year-over-year?
- Taysha Gene Therapies, Inc.'s cash ratio increased by 166.2% year-over-year, from 5.2× to 13.8×.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s cash ratio?
- Over 5 years (2020 to 2025), Taysha Gene Therapies, Inc.'s cash ratio has grown at a -19.3% compound annual growth rate (CAGR), from 35.2× to 12×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.